Literature DB >> 9886299

Bone disease in multiple myeloma.

P I Croucher1, J F Apperley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9886299     DOI： 10.1046/j.1365-2141.1998.01082.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  16 in total

1.  Vertebral lesion distribution in multiple myeloma--assessed by reduced-dose whole-body MDCT.

Authors:  Georg Bier; Christopher Kloth; Christoph Schabel; Malte Bongers; Konstantin Nikolaou; Marius Horger
Journal:  Skeletal Radiol       Date:  2016-01       Impact factor: 2.199

2.  Predicting multiple myeloma disease activity by analyzing natural calcium isotopic composition.

Authors:  G W Gordon; J Monge; M B Channon; Q Wu; J L Skulan; A D Anbar; R Fonseca
Journal:  Leukemia       Date:  2014-06-12       Impact factor: 11.528

Review 3.  Optimal management of cancer treatment-induced bone loss: considerations for elderly patients.

Authors:  Karen Tipples; Anne Robinson
Journal:  Drugs Aging       Date:  2011-11-01       Impact factor: 3.923

4.  Functional results of vertebral augmentation techniques in pathological vertebral fractures of myelomatous patients.

Authors:  Kamil Cagri Köse; Oguz Cebesoy; Burak Akan; Levent Altinel; Derya Dinçer; Tarik Yazar
Journal:  J Natl Med Assoc       Date:  2006-10       Impact factor: 1.798

5.  Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.

Authors:  Meera Mohan; Rohan S Samant; Donghoon Yoon; Amy F Buros; Antonio Branca; Corey O Montgomery; Richard Nicholas; Larry J Suva; Roy Morello; Sharmilan Thanendrarajan; Carolina Schinke; Shmuel Yaccoby; Frits van Rhee; Faith E Davies; Gareth J Morgan; Maurizio Zangari
Journal:  J Bone Miner Res       Date:  2017-03-27       Impact factor: 6.741

Review 6.  The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.

Authors:  E V McCloskey; J F Guest; J A Kanis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients.

Authors:  Nikolaos Kanellias; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Vassilis Koutoulidis; Despina Fotiou; Magdalini Migkou; Evangelos Eleutherakis-Papaiakovou; Panagiotis Malandrakis; Tina Bagratuni; Stylianos Mavropoulos-Papoudas; Maria Roussou; Efstathios Kastritis; Lia A Moulopoulos; Meletios A Dimopoulos; Evangelos Terpos
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

8.  Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma.

Authors:  Agatha Labrinidis; Peter Diamond; Sally Martin; Shelley Hay; Vasilios Liapis; Irene Zinonos; Natalie A Sims; Gerald J Atkins; Cristina Vincent; Vladimir Ponomarev; David M Findlay; Andrew C W Zannettino; Andreas Evdokiou
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

9.  International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

Authors:  Evangelos Terpos; Gareth Morgan; Meletios A Dimopoulos; Matthew T Drake; Suzanne Lentzsch; Noopur Raje; Orhan Sezer; Ramón García-Sanz; Kazuyuki Shimizu; Ingemar Turesson; Tony Reiman; Artur Jurczyszyn; Giampaolo Merlini; Andrew Spencer; Xavier Leleu; Michele Cavo; Nikhil Munshi; S Vincent Rajkumar; Brian G M Durie; G David Roodman
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

Review 10.  Multiple myeloma in the marrow: pathogenesis and treatments.

Authors:  Heather Fairfield; Carolyne Falank; Lindsey Avery; Michaela R Reagan
Journal:  Ann N Y Acad Sci       Date:  2016-01       Impact factor: 5.691
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.